HALO
Halozyme Therapeutics, Inc.
HALO has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over HALO overall, supported by stronger fundamentals and stronger valuation.
HALO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Under pressure |
HALO's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HALO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $101 | — |
| Cheap | 15x | $60.40 | -40% |
| Fair | 21x | $84.87 | -16% |
| Current | 25x | $101 | — |
| Expensive | 35x | $139 | +38% |
Historical ranges are pointers, not guarantees.
HALO's PE is in its fair range at 25x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over HALO in the historical PE scenario, which offers more potential upside but is not a forecast.
HALO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for HALO, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
HALO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.06 | +151% |
| Q3 2026 | $4.00 | -16% |
| Q2 2026 | $3.42 | -22% |
| Q1 2026 | $2.85 | -24% |
| Q4 2025 | $2.56 | -25% |
| Q3 2025 | $4.75 | +58% |
| Q2 2025 | $4.37 | +70% |
| Q1 2025 | $3.76 | +56% |
| Q4 2024 | $3.43 | +63% |
HALO earned $4.00 per share over the past year, down 16% from the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
HALO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $493M | +39% |
| Q2 2026 | $481M | +48% |
| Q1 2026 | $376.7M | +42% |
| Q4 2025 | $451.8M | +52% |
| Q3 2025 | $354.3M | +22% |
| Q2 2025 | $325.7M | +41% |
| Q1 2025 | $264.9M | +35% |
| Q4 2024 | $298M | +30% |
HALO's revenue has grown year over year for 19 quarters in a row: $493M last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 60% | -1.7 points |
| Q2 2026 | 60% | -2.4 points |
| Q1 2026 | 49% | -4.5 points |
| Q4 2025 | -21% | -80 points |
| Q3 2025 | 62% | +5.3 points |
| Q2 2025 | 62% | +12 points |
| Q1 2025 | 53% | +4.7 points |
| Q4 2024 | 59% | +15 points |
HALO has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over HALO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
HALO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $255.2M | +45% |
| Q2 2026 | $236.7M | +141% |
| Q1 2026 | $176.3M | +15% |
| Q4 2025 | $217.6M | +24% |
| Q3 2025 | $175.6M | +54% |
| Q2 2025 | $98.1M | +84% |
| Q1 2025 | $153.3M | +22% |
| Q4 2024 | $175.4M | +76% |
HALO has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
HALO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.4M shares |
| 1 year | +0.2% | +280K shares |
| 3 years | -8.6% | -11.5M shares |
| 5 years | -16% | -24.1M shares |
| Available history | -13% | -18.4M shares |
HALO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $67.3M |
| Q4 2025 | — |
| Q3 2025 | $38.9M |
| Q4 2024 | $250M |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $252.3M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HALO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.2x | Elevated |
| Q2 2026 | 3.2x | Elevated |
| Q1 2026 | 3.5x | Elevated |
| Q4 2025 | 4.2x | High |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 2.1x | Moderate |
| Q1 2025 | 2.2x | Moderate |
| Q4 2024 | 2.5x | Moderate |
HALO's net debt is about 3.2 years of its operating earnings (EBITDA), up from 1.5 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over HALO on leverage, with a lower net debt burden relative to earnings.
HALO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 47.7 | Neutral |
HALO's weekly RSI is 51 (neutral) and its Stochastic is 48 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
HALO PE vs Healthcare Sector
| Metric | HALO | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 2.6% below |
| PE % | 65 | 29 | 36 pts above |
HALO is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over HALO on valuation relative to its sector.
HALO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $114.6 | 12% below |
| 20 week MA | $103.0 | 2.3% below |
| 50 week MA | $82.3 | 22% above |
| 100 week MA | $71.8 | 40% above |
| 200 week MA | $57.6 | 75% above |
HALO has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 75% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over HALO on trend strength, trading above more of its moving averages.
HALO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.0 | $42.9 | +139% |
| 2021 | $42.9 | $40.2 | -6.2% |
| 2022 | $40.2 | $57.5 | +43% |
| 2023 | $57.5 | $37.0 | -36% |
| 2024 | $37.0 | $48.1 | +30% |
| 2025 | $48.1 | $68.9 | +43% |
| 2026 YTD | $68.9 | $100.7 | +46% |
HALO has finished higher in four of the last six years. It's up 46% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over HALO on returns for 2026, with the stronger performance.